Repaglinide 1 mg (Generic)

Product Overview

Repaglinide 1 mg is a generic oral antidiabetic medication supplied by Novo Nordisk India. Each strip contains 15 tablets, and the product is available in pack sizes of 30, 60, or 90 tablets. It is indicated for the treatment of type 2 diabetes mellitus when lifestyle modification alone does not achieve adequate glycemic control. The medication is formulated to complement diet and exercise, offering a flexible dosing schedule that can be adjusted according to individual patient response. Shipping typically takes 6 to 15 days, ensuring timely delivery for patients across various regions.

What is Repaglinide

Repaglinide belongs to the meglitinide class of antidiabetic agents. It functions by stimulating pancreatic beta cells to release insulin in a glucose‑dependent manner. Unlike some other oral hypoglycemics, repaglinide has a rapid onset and short duration of action, making it particularly suitable for controlling post‑prandial glucose spikes. The drug is chemically identified as a synthetic derivative of benzoic acid and is marketed under the generic name repaglinide with a strength of 1 mg per tablet. Its pharmacokinetic profile supports once‑daily or multiple‑times‑daily administration, depending on the prescribed regimen.

Uses and Benefits

The primary use of repaglinide is to lower blood glucose levels in adults with type 2 diabetes who have not achieved target HbA1c values through diet and exercise alone. Clinical studies demonstrate that repaglinide effectively reduces fasting and post‑prandial glucose concentrations, thereby decreasing the risk of long‑term complications such as cardiovascular disease, nephropathy, and retinopathy. Additional benefits include its compatibility with other oral antidiabetic agents and insulin, allowing individualized combination therapy. Patients often appreciate the flexibility of titrating the dose based on meal patterns, which can improve adherence and quality of life.

How It Works

Repaglinide exerts its antihypertensive effect by binding to the ATP‑dependent potassium (K‑ATP) channel on pancreatic beta cells. This interaction leads to closure of the channel, depolarization of the cell membrane, and subsequent influx of calcium ions, triggering insulin secretion. Because the drug’s action is glucose‑dependent, insulin release is proportional to the current blood glucose level, minimizing the risk of hypoglycemia when used as monotherapy. The rapid onset (within 30 minutes) and short half‑life (approximately 1 hour) enable precise control of post‑meal glucose excursions, a key advantage over longer‑acting sulfonylureas.

Dosage Guidelines

Treatment typically begins with a 0.5 mg dose taken before the largest meal of the day. The dose may be titrated upward in increments of 0.5 mg, up to a maximum of 4 mg per day, based on glycemic response and tolerability. Dose adjustments are recommended for patients with renal impairment (creatinine clearance <60 mL/min) and for elderly patients, who may require a lower starting dose. It is essential to take repaglinide shortly before meals; if a meal is skipped, the corresponding dose should be omitted. Regular monitoring of blood glucose levels guides dose modifications, ensuring optimal control while avoiding excessive lowering of glucose.

Side Effects

Most patients tolerate repaglinide well, but some may experience adverse effects. Common side effects include headache, dizziness, and mild hypoglycemia, especially when combined with other glucose‑lowering agents. Less frequent but clinically important events comprise liver enzyme elevations, skin rash, and weight gain. Rarely, serious hepatic dysfunction or severe hypoglycemia may occur, necessitating immediate discontinuation and medical evaluation. Patients should be advised to report any persistent or worsening symptoms to their healthcare provider promptly.

Warnings and Precautions

Repaglinide is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is advised in patients with moderate to severe hepatic impairment, as the drug is primarily metabolized by the liver. Use during pregnancy should only occur if the potential benefit justifies the potential risk to the fetus, and breastfeeding is generally discouraged. Concomitant use with certain drugs that induce or inhibit hepatic enzymes may alter repaglinide levels, requiring dose adjustments. Additionally, patients should be educated about the signs of hypoglycemia and instructed to carry a source of glucose at all times.

Frequently Asked Questions

1. Can repaglinide be used alone for glycemic control? Yes, repaglinide can be used as monotherapy in patients who respond adequately to a single oral agent, but many clinicians combine it with metformin or other agents for enhanced efficacy.
2. How does repaglinide differ from metformin? Repaglinide stimulates insulin secretion in a glucose‑dependent manner, while metformin reduces hepatic glucose production and improves insulin sensitivity; they act through distinct mechanisms and are often used together.
3. Is dose adjustment needed for elderly patients? Elderly individuals often start at a lower dose (0.5 mg) and may require slower titration due to increased sensitivity and potential for hypoglycemia.
4. What should I do if I miss a dose? If a dose is missed and the next meal is several hours away, the dose can be taken; however, if it is close to the next scheduled dose, skip the missed dose and resume the regular schedule.
5. Are there any dietary restrictions while taking repaglinide? No specific dietary restrictions are required, but maintaining a consistent carbohydrate intake and taking the medication before meals optimizes glucose control.

Related Products

• Okamet 500 Mg (Metformin)
• Novofine 31G Needle (Device)
• Glimepiride 2 mg (Generic)
• Glimepiride 1 mg (Generic)
• Glycomet-GP 0.5 Forte (Metformin/Glimepiride)
• Glycomet-GP 0.5 Tablet (Metformin/Glimepiride)
• Forxiga 5mg (Dapagliflozin)
• Glycomet-GP 1 Tablet (Metformin/Glimepiride)
• Amaryl M 1mg (Metformin/Glimepiride)
• Glycomet-GP 2 Forte (Metformin/Glimepiride)
• Glycomet-GP 1 Forte (Metformin/Glimepiride)
• Glimepiride 4 mg (Generic)